We are live on !
Find out more
Profund Advisors Portfolio holdings
AUM
$3.48B
Turnover
14.37%
1-Year Est. Return
66.96%
ProFund Advisors manages the ProFunds mutual funds, which include index funds across sectors, bonds, currencies and crypto, as well as leveraged and inverse funds. The ProFunds brand dates from 1997, and its affiliate ProShares began offering leveraged and inverse ETFs in 2006. The Bitcoin ProFund tracks bitcoin futures rather than holding bitcoin itself.
This Fund
S&P 500
This Quarter Est. Return
+4.18%
1 Year Est. Return
+66.96%
3 Year Est. Return
+258.11%
5 Year Est. Return
+342.15%
10 Year Est. Return
+1,333.1%
AUM
$2.05B
AUM Growth
+$125M
(+6.5%)
Cap. Flow
+$74.8M
Cap. Flow % of AUM
Cap. Flow %
3.64%
Top 10 Holdings %
Top 10 Hldgs %
22.74%
Holding
1,533
New
82
Increased
902
Reduced
480
Closed
69
Avg Time Held
2.1
years
Top 10 Avg Time Held
1.9
years
Top 20 Avg Time Held
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AT&T
T
|
+$30.9M |
| 2 |
Verizon
VZ
|
+$26.8M |
| 3 |
ExxonMobil
XOM
|
+$6.68M |
| 4 |
SLB Ltd
SLB
|
+$3.54M |
| 5 |
Chevron
CVX
|
+$3.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BXLT
BAXALTA INC COM STK (DE)
BXLT
|
+$15.9M |
| 2 |
Gilead Sciences
GILD
|
+$5.42M |
| 3 |
Amgen
AMGN
|
+$3.44M |
| 4 |
Apple
AAPL
|
+$3.34M |
| 5 |
CELG
Celgene Corp
CELG
|
+$2.83M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 26.52% |
| 2 | Communication Services | 12.3% |
| 3 | Technology | 11.53% |
| 4 | Energy | 7.73% |
| 5 | Financials | 7.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Amgen
AMGN
$252B
| $68.4M | 3.33% |
449,840
-22,101
| -5% | -$3.44M |
2013 Q2
12 quarters
|
|
|
2
Gilead Sciences
GILD
$208B
| $66.5M | 3.24% |
797,109
-61,062
| -7% | -$5.42M |
2013 Q2
12 quarters
|
|
3
AbbVie
ABBV
$521B
| $55.2M | 2.69% |
891,107
-40,236
| -4% | -$2.45M |
2013 Q2
12 quarters
|
|
|
4
AT&T
T
$149B
| $55.2M | 2.69% |
1,690,348
+1,037,337
| +159% | +$30.9M |
2013 Q2
12 quarters
|
|
|
5
Verizon
VZ
$192B
| $47.5M | 2.31% |
850,535
+516,538
| +155% | +$26.8M |
2013 Q2
12 quarters
|
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $45.7M | 2.23% |
463,540
-27,394
| -6% | -$2.83M |
2013 Q2
12 quarters
|
|
|
7
Apple
AAPL
$5.18T
| $35M | 1.7% |
1,463,828
-134,464
| -8% | -$3.34M |
2013 Q2
12 quarters
|
|
8
Biogen
BIIB
$37.5B
| $31.7M | 1.54% |
131,050
-6,248
| -5% | -$1.65M |
2013 Q2
12 quarters
|
|
9
Amazon
AMZN
$2.88T
| $31.4M | 1.53% |
878,580
-78,400
| -8% | -$2.65M |
2013 Q2
12 quarters
|
|
|
10
ExxonMobil
XOM
$696B
| $30.6M | 1.49% |
326,024
+75,514
| +30% | +$6.68M |
2013 Q2
12 quarters
|
|
11
Microsoft
MSFT
$3.89T
| $26.8M | 1.3% |
523,068
-44,718
| -8% | -$2.32M |
2013 Q2
12 quarters
|
|
12
Meta Platforms (Facebook)
META
$1.64T
| $24M | 1.17% |
209,655
-11,860
| -5% | -$1.37M |
2013 Q2
12 quarters
|
|
13
Johnson & Johnson
JNJ
$688B
| $22M | 1.07% |
180,978
-16,594
| -8% | -$1.89M |
2013 Q2
12 quarters
|
|
14
Alphabet (Google) Class C
GOOG
$3.6T
| $18.3M | 0.89% |
529,200
-30,900
| -6% | -$1.11M |
2013 Q2
12 quarters
|
|
15
Alphabet (Google) Class A
GOOGL
$3.64T
| $16.9M | 0.82% |
481,420
-22,080
| -4% | -$810K |
2015 Q4
2 quarters
|
|
16
Regeneron Pharmaceuticals
REGN
$98.8B
| $16.7M | 0.81% |
47,872
-2,457
| -5% | -$946K |
2013 Q2
12 quarters
|
|
|
17
Chevron
CVX
$429B
| $15.8M | 0.77% |
151,045
+34,765
| +30% | +$3.5M |
2013 Q2
12 quarters
|
|
|
ALXN
18
DELISTED
Alexion Pharmaceuticals
ALXN
| $15.7M | 0.76% |
134,066
-7,447
| -5% | -$1.06M |
2013 Q2
12 quarters
|
|
19
Pfizer
PFE
$165B
| $13.8M | 0.67% |
414,112
-36,275
| -8% | -$1.16M |
2013 Q2
12 quarters
|
|
20
Intel
INTC
$317B
| $13.7M | 0.67% |
417,035
-30,402
| -7% | -$952K |
2013 Q2
12 quarters
|
|
21
Vertex Pharmaceuticals
VRTX
$137B
| $12.7M | 0.62% |
147,881
-6,508
| -4% | -$562K |
2013 Q2
12 quarters
|
|
22
Illumina
ILMN
$31.3B
| $12.4M | 0.6% |
90,637
-4,200
| -4% | -$597K |
2013 Q2
12 quarters
|
|
23
Comcast
CMCSA
$89.3B
| $12.2M | 0.6% |
375,450
-32,188
| -8% | -$999K |
2013 Q2
12 quarters
|
|
|
24
SLB Ltd
SLB
$76.3B
| $11.6M | 0.56% |
146,408
+46,145
| +46% | +$3.54M |
2013 Q2
12 quarters
|
|
25
Merck
MRK
$364B
| $10.5M | 0.51% |
190,849
-15,433
| -7% | -$821K |
2013 Q2
12 quarters
|
|
Similar funds
TC
SHIM
Profund Advisors's Q2 2016 Portfolio in Review
As of Q2 2016, Profund Advisors held 1,533 positions worth $2.05B, up 6.5% from $1.93B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Profund Advisors deployed $74.8M of net new capital in Q2 2016, opening 82 new positions and adding to 902 existing holdings. Its largest new stake was Brocade Communications Systems, Inc. NEW: 79,318 shares worth $728K.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 31% a quarter earlier, followed by Communication Services and Technology.
On the sell side, the largest reduction was Gilead Sciences, an estimated $5.42M trimmed.
- Profund Advisors's largest Q2 2016 buy was Brocade Communications Systems, Inc. NEW: 79,318 shares worth $728K.
- Profund Advisors added most to AT&T in Q2 2016, an estimated $30.9M increase.
- Profund Advisors's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $5.42M.
- Profund Advisors fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $15.9M.
- Profund Advisors's ten largest holdings make up 23% of its $2.05B portfolio in Q2 2016.
- Profund Advisors opened 82 new positions and closed 69 in Q2 2016.
- Profund Advisors's portfolio value rose 6.5% quarter-over-quarter to $2.05B.
Based on Profund Advisors's 13F filing for Q2 2016, filed 12 Aug 2016.